Welcome to our dedicated page for Sigmatron Intl SEC filings (Ticker: SGMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SigmaTron International, Inc. (former Nasdaq: SGMA) SEC filings page on Stock Titan provides historical access to the company’s public reporting as an independent electronic manufacturing services (EMS) provider. Before its acquisition by an affiliate of Transom Capital Group, SigmaTron filed annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that detailed its EMS segment, which includes printed circuit board assemblies, electro-mechanical subassemblies and box-build electronic products produced across facilities in the United States, Mexico, China and Vietnam, with procurement and compliance operations in Taipei, Taiwan.
For investors researching SGMA, key filings include current reports on Form 8-K describing material events such as the May 20, 2025 Agreement and Plan of Merger with Transom Axis AcquireCo, LLC and Transom Axis MergerSub, Inc., subsequent updates to the tender offer timing, and the July 28, 2025 8-K reporting completion of the acquisition. That 8-K also outlines the treatment of common shares, stock options and warrants in the merger, the change in control, amendments to SigmaTron’s certificate of incorporation and bylaws, and changes to the board of directors.
Another important document is the Form 25 filed on July 28, 2025 by The Nasdaq Stock Market LLC, which serves as the notification of removal from listing and/or registration of SigmaTron International, Inc. common stock under Section 12(b) of the Securities Exchange Act of 1934. The July 28, 2025 8-K further indicates that SigmaTron intends to file a Form 15 to terminate registration of its shares under Section 12(g) and suspend its reporting obligations under Sections 13 and 15(d).
On Stock Titan, users can review these historical filings and use AI-powered summaries to understand the significance of each document, from merger-related 8-Ks and delisting notices on Form 25 to periodic reports that discuss SigmaTron’s EMS operations, financial condition and risk factors prior to its transition to private ownership.
SigmaTron International, Inc. (SGMA) has filed a Schedule 14D-9 in response to a cash tender offer launched by Transom Axis MergerSub, Inc., a wholly-owned subsidiary of Transom Axis AcquireCo, LLC. The offer seeks to acquire all outstanding SigmaTron common shares for $3.02 per share in cash, subject to customary withholding taxes.
Key share statistics as of 2 June 2025 include:
- 6,119,288 common shares outstanding
- 793,956 shares issuable under outstanding employee stock options
- 1,223,250 shares underlying outstanding warrants
- No treasury or preferred shares
The offer is being made pursuant to a Merger Agreement dated 20 May 2025. Following successful completion of the tender and satisfaction of closing conditions, Purchaser will merge with and into SigmaTron under DGCL §251(h), making SigmaTron a wholly-owned subsidiary of Transom. All untendered shares (other than excluded or appraisal shares) will convert into the same $3.02 cash consideration at the effective time.
Principal conditions include:
- Minimum tender: more than 50% of outstanding shares
- Accuracy of SigmaTron representations & warranties
- Performance of covenants
- No Company Material Adverse Effect
Either party may terminate the Merger Agreement if the Offer Acceptance Time has not occurred by the End Date. SigmaTron’s board considered the arrangements and potential conflicts disclosed in Item 3 while negotiating the transaction. Stockholders may obtain free copies of the Offer to Purchase, Letter of Transmittal and this Schedule 14D-9 at the SEC’s website or through the information agent D.F. King & Co.
SigmaTron International, Inc. (SGMA) filed a Schedule 14D-9C to inform shareholders that it has received a waiver permitting Transom Axis MergerSub, Inc. to extend the contractual deadline for commencing its previously announced tender offer for all outstanding SGMA common shares under the May 20, 2025 Agreement and Plan of Merger.
The filing references and incorporates the Company’s Current Report on Form 8-K filed June 20, 2025 (attached as Exhibit 99.1). No tender offer has begun; once launched, Transom and MergerSub will file Schedule TO materials and SigmaTron will issue a full Solicitation/Recommendation Statement on Schedule 14D-9.
The document reiterates that the forthcoming tender offer materials will contain essential information for shareholders’ decision-making and will be available without charge on both the Company’s website and the SEC’s EDGAR system.
A detailed forward-looking statement disclaimer highlights numerous risks that could affect the timing and completion of the transaction, including: (i) shareholder participation levels, (ii) competing bids, (iii) regulatory approvals, (iv) satisfaction of closing conditions, and (v) potential litigation or macroeconomic factors. The Company disclaims any obligation to update these forward-looking statements.
In short, the filing is an administrative update signalling that the merger process remains active but will progress on a slightly revised timetable.
On 20 June 2025 SigmaTron International, Inc. (NASDAQ: SGMA) filed a Form 8-K under Item 8.01 to report a waiver to its 20 May 2025 Agreement and Plan of Merger with Transom Axis AcquireCo, LLC and Transom Axis MergerSub, Inc. The waiver extends the deadline for MergerSub to commence its all-cash tender offer for all outstanding SigmaTron shares from 18 June 2025 to 26 June 2025, or such later date as the parties may mutually agree.
No other terms of the merger were amended. The only exhibit furnished is the waiver itself (Exhibit 99.1). The tender offer has not yet begun; when launched, Transom and MergerSub will file a Schedule TO, and SigmaTron will file a Schedule 14D-9. The company reiterates that shareholders should review those documents carefully when available.
Forward-looking statements in the filing warn of customary risks, including regulatory approvals, shareholder tender levels, competing bids, and potential litigation. No financial statements, earnings data, or pro-forma information were included in this report.
Aside from the eight-day extension, the merger timeline and considerations remain unchanged.